MY196333A - Intranasal Composition Comprising Betahistine - Google Patents
Intranasal Composition Comprising BetahistineInfo
- Publication number
- MY196333A MY196333A MYPI2019004366A MYPI2019004366A MY196333A MY 196333 A MY196333 A MY 196333A MY PI2019004366 A MYPI2019004366 A MY PI2019004366A MY PI2019004366 A MYPI2019004366 A MY PI2019004366A MY 196333 A MY196333 A MY 196333A
- Authority
- MY
- Malaysia
- Prior art keywords
- betahistine
- intranasal composition
- intranasal
- otological
- present disclosure
- Prior art date
Links
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004536 betahistine Drugs 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453931P | 2017-02-02 | 2017-02-02 | |
| PCT/EP2018/052695 WO2018141922A1 (en) | 2017-02-02 | 2018-02-02 | Intranasal composition comprising betahistine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY196333A true MY196333A (en) | 2023-03-24 |
Family
ID=61187302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019004366A MY196333A (en) | 2017-02-02 | 2018-02-02 | Intranasal Composition Comprising Betahistine |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10456386B2 (OSRAM) |
| EP (2) | EP3474850B1 (OSRAM) |
| JP (3) | JP7714323B2 (OSRAM) |
| KR (1) | KR102653545B1 (OSRAM) |
| CN (2) | CN110418643A (OSRAM) |
| AR (1) | AR111699A1 (OSRAM) |
| AU (1) | AU2018216970B2 (OSRAM) |
| CA (1) | CA3051725A1 (OSRAM) |
| CL (1) | CL2019002145A1 (OSRAM) |
| CO (1) | CO2019008657A2 (OSRAM) |
| DK (2) | DK3698791T3 (OSRAM) |
| EA (1) | EA201991817A1 (OSRAM) |
| ES (2) | ES2807798T3 (OSRAM) |
| FI (1) | FI3698791T3 (OSRAM) |
| HR (2) | HRP20201137T1 (OSRAM) |
| HU (2) | HUE065336T2 (OSRAM) |
| IL (1) | IL268353B2 (OSRAM) |
| LT (2) | LT3698791T (OSRAM) |
| MA (1) | MA46778B1 (OSRAM) |
| MX (1) | MX381932B (OSRAM) |
| MY (1) | MY196333A (OSRAM) |
| NZ (1) | NZ755931A (OSRAM) |
| PH (1) | PH12019501785B1 (OSRAM) |
| PL (2) | PL3474850T3 (OSRAM) |
| PT (2) | PT3474850T (OSRAM) |
| RS (2) | RS65099B1 (OSRAM) |
| SA (1) | SA519402324B1 (OSRAM) |
| SG (1) | SG11201906980YA (OSRAM) |
| SI (2) | SI3698791T1 (OSRAM) |
| TN (1) | TN2019000220A1 (OSRAM) |
| TW (1) | TWI760429B (OSRAM) |
| WO (1) | WO2018141922A1 (OSRAM) |
| ZA (1) | ZA201904955B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170532A1 (en) * | 2017-03-22 | 2018-09-27 | Franz, Lilian Ann | Treatment method |
| CA3179806A1 (en) * | 2020-04-14 | 2021-10-21 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Nasal spray formulation with moisturizing benefits |
| WO2021214547A1 (en) * | 2020-04-22 | 2021-10-28 | Sanotize Research And Development Corp. | Compositions and methods for treating upper respiratory infections |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397840B1 (OSRAM) | 1977-07-22 | 1981-03-20 | Cherqui Jean | |
| IT1229237B (it) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | Sali di (2-(piridil)etil) metilammina |
| JPH03287535A (ja) * | 1990-03-31 | 1991-12-18 | Bairon Boeki Kk | プラノプロフェン水溶液 |
| JP3203056B2 (ja) * | 1992-08-13 | 2001-08-27 | 株式会社ティ・ティ・エス技術研究所 | メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤 |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| JPH10139667A (ja) * | 1996-11-15 | 1998-05-26 | Yoshitomi Pharmaceut Ind Ltd | 水性液剤 |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP3555598B2 (ja) | 2001-06-27 | 2004-08-18 | 株式会社村田製作所 | 積層型インダクタ |
| JP2004196676A (ja) * | 2002-12-16 | 2004-07-15 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
| JP4733333B2 (ja) * | 2002-12-26 | 2011-07-27 | ライオン株式会社 | 点鼻剤又は洗鼻剤 |
| DK1530965T3 (da) | 2003-11-11 | 2006-07-17 | Mattern Udo | Kontrolleret frigivelsesleveringssystem til nasal applikation |
| WO2005101979A2 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| AU2006202950A1 (en) * | 2004-04-22 | 2006-10-19 | Mor Research Applications Ltd. | Methods and Compositions for Weight Management |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| EP2457580A1 (en) | 2004-08-25 | 2012-05-30 | The UAB Research Foundation | Absorption enhancers for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| JP2009504767A (ja) * | 2005-08-17 | 2009-02-05 | フレミング・アンド・カンパニー・ファーマシューティカルズ | ビタミンｂ１２鼻用スプレーおよび使用方法 |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| WO2007076140A2 (en) | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| JP2011507895A (ja) | 2007-12-21 | 2011-03-10 | シェーリング−プラウ ヘルスケア プロダクツ，インコーポレイテッド | オキシメタゾリンの増強された光安定化 |
| EP2278999B1 (en) * | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| PT2293794E (pt) | 2008-05-27 | 2013-07-10 | Univ Melbourne | Métodos de tratamento de mamíferos com disfunções da trompa de eustáquio |
| WO2010042759A2 (en) * | 2008-10-08 | 2010-04-15 | Kyphia Pharmaceuticals Inc | Gaba conjugates and methods of use thereof |
| WO2016049700A1 (en) * | 2014-10-03 | 2016-04-07 | Lachesis Biosciences Pty Ltd | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
-
2018
- 2018-02-02 CN CN201880017726.2A patent/CN110418643A/zh active Pending
- 2018-02-02 LT LTEP20170448.3T patent/LT3698791T/lt unknown
- 2018-02-02 TN TNP/2019/000220A patent/TN2019000220A1/en unknown
- 2018-02-02 CA CA3051725A patent/CA3051725A1/en active Pending
- 2018-02-02 CN CN202410176958.XA patent/CN118356397A/zh active Pending
- 2018-02-02 SI SI201831043T patent/SI3698791T1/sl unknown
- 2018-02-02 SI SI201830082T patent/SI3474850T1/sl unknown
- 2018-02-02 JP JP2019541717A patent/JP7714323B2/ja active Active
- 2018-02-02 US US15/887,388 patent/US10456386B2/en active Active
- 2018-02-02 AR ARP180100254A patent/AR111699A1/es not_active Application Discontinuation
- 2018-02-02 NZ NZ755931A patent/NZ755931A/en unknown
- 2018-02-02 IL IL268353A patent/IL268353B2/en unknown
- 2018-02-02 WO PCT/EP2018/052695 patent/WO2018141922A1/en not_active Ceased
- 2018-02-02 ES ES18703749T patent/ES2807798T3/es active Active
- 2018-02-02 HU HUE20170448A patent/HUE065336T2/hu unknown
- 2018-02-02 DK DK20170448.3T patent/DK3698791T3/da active
- 2018-02-02 HR HRP20201137TT patent/HRP20201137T1/hr unknown
- 2018-02-02 FI FIEP20170448.3T patent/FI3698791T3/fi active
- 2018-02-02 MA MA46778A patent/MA46778B1/fr unknown
- 2018-02-02 EA EA201991817A patent/EA201991817A1/ru unknown
- 2018-02-02 LT LTEP18703749.4T patent/LT3474850T/lt unknown
- 2018-02-02 PL PL18703749T patent/PL3474850T3/pl unknown
- 2018-02-02 PT PT187037494T patent/PT3474850T/pt unknown
- 2018-02-02 RS RS20240022A patent/RS65099B1/sr unknown
- 2018-02-02 HU HUE18703749A patent/HUE050829T2/hu unknown
- 2018-02-02 AU AU2018216970A patent/AU2018216970B2/en active Active
- 2018-02-02 EP EP18703749.4A patent/EP3474850B1/en active Active
- 2018-02-02 EP EP20170448.3A patent/EP3698791B1/en active Active
- 2018-02-02 DK DK18703749.4T patent/DK3474850T3/da active
- 2018-02-02 MX MX2019008961A patent/MX381932B/es unknown
- 2018-02-02 TW TW107103800A patent/TWI760429B/zh active
- 2018-02-02 MY MYPI2019004366A patent/MY196333A/en unknown
- 2018-02-02 ES ES20170448T patent/ES2969301T3/es active Active
- 2018-02-02 RS RS20200851A patent/RS60554B1/sr unknown
- 2018-02-02 PH PH1/2019/501785A patent/PH12019501785B1/en unknown
- 2018-02-02 PL PL20170448.3T patent/PL3698791T3/pl unknown
- 2018-02-02 PT PT201704483T patent/PT3698791T/pt unknown
- 2018-02-02 KR KR1020197025622A patent/KR102653545B1/ko active Active
- 2018-02-02 HR HRP20231706TT patent/HRP20231706T1/hr unknown
- 2018-02-02 SG SG11201906980YA patent/SG11201906980YA/en unknown
-
2019
- 2019-07-26 SA SA519402324A patent/SA519402324B1/ar unknown
- 2019-07-29 ZA ZA2019/04955A patent/ZA201904955B/en unknown
- 2019-07-30 CL CL2019002145A patent/CL2019002145A1/es unknown
- 2019-08-09 CO CONC2019/0008657A patent/CO2019008657A2/es unknown
- 2019-09-13 US US16/570,156 patent/US20200022963A1/en not_active Abandoned
-
2022
- 2022-02-08 JP JP2022017792A patent/JP2022051872A/ja not_active Withdrawn
-
2024
- 2024-01-04 JP JP2024000158A patent/JP2024019731A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| MY196072A (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| SA520411843B1 (ar) | Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات | |
| MX2023000255A (es) | Formas de dosificacion de ruxolitinib de liberacion sostenida. | |
| MX2019002439A (es) | Derivados de n-(piridin-2-il) piridina-sulfonamida y su uso en el tratamiento de enfermedades. | |
| NZ729252A (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| PH12015502365B1 (en) | Bace1 inhibitors | |
| AU2017312811A8 (en) | Liquid naloxone spray | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| MY196333A (en) | Intranasal Composition Comprising Betahistine | |
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| MX368641B (es) | Compuestos para el tratamiento de inflamación y dolor. | |
| WO2013038200A3 (en) | Neurodevelopmental disorders | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| WO2018084817A3 (en) | A new form of active agent | |
| NZ801355A (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| MY203647A (en) | Sustained-release dosage forms of ruxolitinib | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| PL410369A1 (pl) | Nowe pochodne peptydowe, sposób ich otrzymywania, kompozycja farmaceutyczna, kompozycja dezynfekująca oraz zastosowanie i zestaw |